Cybin (CYBN) said Tuesday that the US Patent and Trademark Office has granted the company a patent in support of its CYB004 deuterated dimethyltryptamine program for the treatment of generalized anxiety disorder.

The patent, which is expected to provide exclusivity until 2040, includes its claims to novel formulations of dimethyltryptamine and deuterated isotopologues for intramuscular injection, the company said.

Shares of the biotech firm fell by more than 1% in recent premarket activity.